[1] Chen KY,Curtis N,Dahdah N, et al. Kawasaki disease and cardiovascular risk: a comprehensive review of subclinical vascular changes in the longer term[J]. Acta Paediatr, 2016, 105(7): 752-761. DOI: 10.1111/apa.13367.
[2] Yan Y,Ma Y,Liu Y, et al. Combined analysis of genome-wide-linked susceptibility loci to Kawasaki disease in Han Chinese[J]. Hum Genet, 2013, 132(6): 669-680. DOI: 10.1007/s00439-013-1279-2.
[3] Duan J,Lou J,Zhang Q, et al. A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease: a case-control study and meta-analysis[J]. PLoS One, 2014, 9(8): e103329. DOI: 10.1371/journal.pone.0103329.
[4] Khor CC,Davila S,Shimizu C, et al. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease[J]. J Med Genet, 2011, 48(7): 467-472. DOI: 10.1136/jmg.2010.086611.
[5] Newburger JW,Takahashi M,Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Circulation, 2004, 110(17): 2747-2771. DOI: 10.1161/01.CIR.0000145143.19711.78.
[6] Rowley AH. Kawasaki disease: novel insights into etiology and genetic susceptibility[J]. Annu Rev Med, 2011, 62: 69-77. DOI: 10.1146/annurev-med-042409-151944.
[7] Kuo HC,Chang WC. Genetic polymorphisms in Kawasaki disease[J]. Acta Pharmacol Sin, 2011, 32(10): 1193-1198. DOI: 10.1038/aps.2011.93.
[8] Geva R,Vecchione L,Kalogeras KT, et al. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study[J]. Gut, 2015, 64(6): 921-928. DOI: 10.1136/gutjnl-2014-307234.
[9] Kuo HC,Chang JC,Kuo HC, et al. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array[J]. Arthritis Rheumatol, 2015, 67(3): 828-836. DOI: 10.1002/art.38976.
[10] Li R,Peng H,Chen GM, et al. Association of FCGR2A-R/H131 polymorphism with susceptibility to systemic lupus erythematosus among Asian population: a meta-analysis of 20 studies[J]. Arch Dermatol Res, 2014, 306(9): 781-791. DOI: 10.1007/s00403-014-1483-5.
[11] Khor CC,Davila S,Breunis WB, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease[J]. Nat Genet, 2011, 43(12): 1241-1246. DOI: 10.1038/ng.981.
[12] Wu YY,Georg I,Díaz-Barreiro A, et al. Concordance of increased B1 cell subset and lupus phenotypes in mice and humans is dependent on BLK expression levels[J]. J Immunol, 2015, 194(12): 5692-5702. DOI: 10.4049/jimmunol.1402736.
[13] Onouchi Y,Ozaki K,Burns JC, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease[J]. Nat Genet, 2012, 44(5): 517-521. DOI: 10.1038/ng.2220.
[14] Yu DM,Huynh T,Truong AM, et al. ABC transporters and neuroblastoma[J]. Adv Cancer Res, 2015, 125: 139-170. DOI: 10.1016/bs.acr.2014.10.005.